MCID: THR005
MIFTS: 63

Thrombotic Thrombocytopenic Purpura

Categories: Blood diseases, Genetic diseases, Rare diseases, Nephrological diseases

Aliases & Classifications for Thrombotic Thrombocytopenic Purpura

MalaCards integrated aliases for Thrombotic Thrombocytopenic Purpura:

Name: Thrombotic Thrombocytopenic Purpura 12 25 37 15 63
Purpura, Thrombotic Thrombocytopenic 76 25 44 73
Microangiopathic Hemolytic Anemia 25 73
Congenital Thrombotic Thrombocytopenic Purpura 73
Familial Thrombotic Thrombocytopenia Purpura 25
Familial Thrombotic Thrombocytopenic Purpura 73
Thrombotic Microangiopathy, Familial 25
Purpura Thrombotic Thrombocytopenic 55
Moschcowitz's Syndrome 12
Moschkowitz Disease 25
Ttp 25

Classifications:



Summaries for Thrombotic Thrombocytopenic Purpura

PubMed Health : 63 About thrombotic thrombocytopenic purpura: Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder. In TTP, blood clots form in small blood vessels throughout the body.The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop.The increased clotting that occurs in TTP also uses up platelets (PLATE-lets) in the blood. Platelets are blood cell fragments that help form blood clots. These cell fragments stick together to seal small cuts and breaks on blood vessel walls and stop bleeding.With fewer platelets available in the blood, bleeding problems can occur. People who have TTP may bleed inside their bodies, underneath the skin, or from the surface of the skin. When cut or injured, they also may bleed longer than normal."Thrombotic" (throm-BOT-ik) refers to the blood clots that form. "Thrombocytopenic" (throm-bo-cy-toe-PEE-nick) means the blood has a lower than normal number of platelets. "Purpura" (PURR-purr-ah) refers to purple bruises caused by bleeding under the skin.Bleeding under the skin also can cause tiny red or purple dots on the skin. These pinpoint-sized dots are called petechiae (peh-TEE-kee-ay). Petechiae may look like a rash.

MalaCards based summary : Thrombotic Thrombocytopenic Purpura, also known as purpura, thrombotic thrombocytopenic, is related to thrombotic thrombocytopenic purpura, acquired and thrombotic thrombocytopenic purpura, congenital, and has symptoms including fever and tremor. An important gene associated with Thrombotic Thrombocytopenic Purpura is ADAMTS13 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and O-linked glycosylation. The drugs rituximab and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include kidney, brain and heart, and related phenotypes are proteinuria and hematuria

Genetics Home Reference : 25 Thrombotic thrombocytopenic purpura is a rare disorder that causes blood clots (thrombi) to form in small blood vessels throughout the body. These clots can cause serious medical problems if they block vessels and restrict blood flow to organs such as the brain, kidneys, and heart. Resulting complications can include neurological problems (such as personality changes, headaches, confusion, and slurred speech), fever, abnormal kidney function, abdominal pain, and heart problems.

Wikipedia : 76 Thrombotic thrombocytopenic purpura (TTP) is a rare disorder of the blood-coagulation system, causing... more...

Related Diseases for Thrombotic Thrombocytopenic Purpura

Diseases in the Thrombotic Thrombocytopenic Purpura family:

Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Acquired

Diseases related to Thrombotic Thrombocytopenic Purpura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 241)
# Related Disease Score Top Affiliating Genes
1 thrombotic thrombocytopenic purpura, acquired 35.4 ADAMTS13 VWF
2 thrombotic thrombocytopenic purpura, congenital 35.1 ADAMTS13 CFH
3 spotted fever 30.7 THBD VWF
4 disseminated intravascular coagulation 30.5 ADAMTS13 F3 THBD
5 coronary thrombosis 30.2 F3 VWF
6 hemophilia 30.2 F3 VWF
7 heparin-induced thrombocytopenia 30.2 F3 SELP
8 purpura 30.1 ADAMTS13 APOH F3 THBD VWF
9 hemophilia a 30.1 F3 VWF
10 hepatic veno-occlusive disease 30.0 F3 THBD
11 acute myocardial infarction 29.9 F3 SELP VWF
12 hemolytic-uremic syndrome 29.9 ADAMTS13 CD46 CFH THBD VWF
13 polyarteritis nodosa 29.7 APOH SELE
14 retinal vascular occlusion 29.7 APOH SELP
15 buerger disease 29.6 APOH SELE
16 afibrinogenemia 29.5 CD46 F3 VWF
17 membranoproliferative glomerulonephritis 29.4 CD46 CFH
18 hemorrhagic disease 29.3 ADAMTS13 F3 THBD VWF
19 hemolytic anemia 29.2 ADAMTS13 APOH CFH VWF
20 von willebrand's disease 29.2 ADAMTS13 F3 SELP VWF
21 myocardial infarction 29.1 ADAMTS13 F3 SELP THBD VWF
22 protein s deficiency 29.1 APOH F3
23 essential thrombocythemia 29.1 F3 SELP THBD VWF
24 vasculitis 28.9 APOH SELE THBD VWF
25 thrombophilia 28.3 APOH F3 THBD VWF
26 thrombosis 28.2 APOH F3 SELP THBD VWF
27 systemic lupus erythematosus 28.1 ADAMTS13 APOH F3 SELE THBD VWF
28 placenta disease 28.1 APOH F3
29 antiphospholipid syndrome 27.4 ADAMTS13 APOH F3 SELE SELP THBD
30 vascular disease 26.8 APOH F3 SELE SELP THBD VWF
31 pre-eclampsia 26.8 APOH F3 SELE SELP THBD VWF
32 hellp syndrome 26.5 ADAMTS13 APOH CD46 CFH F3 THBD
33 bombay phenotype 10.8 ADAMTS13 VWF
34 unilateral absence of a pulmonary artery 10.7 THBD VWF
35 autoimmune disease of blood 10.7 ADAMTS13 VWF
36 eisenmenger syndrome 10.7 THBD VWF
37 babesiosis 10.6 ADAMTSL1 THBS1
38 platelet aggregation, spontaneous 10.6 SELP VWF
39 critical limb ischemia 10.6 SELE VWF
40 lupus erythematosus 10.6
41 boutonneuse fever 10.5 SELE THBD
42 vascular cancer 10.5 THBS1 VWF
43 chronic active epstein-barr virus infection 10.5 SELE THBD
44 pancreatitis 10.4
45 quebec platelet disorder 10.4 ADAMTSL1 SELP
46 thrombocytopenia 10.4
47 venous insufficiency 10.4 SELP VWF
48 retinitis 10.4
49 exposure keratitis 10.4 SELE SELP
50 von willebrand disease, type 1 10.4 F3 VWF

Graphical network of the top 20 diseases related to Thrombotic Thrombocytopenic Purpura:



Diseases related to Thrombotic Thrombocytopenic Purpura

Symptoms & Phenotypes for Thrombotic Thrombocytopenic Purpura

Human phenotypes related to Thrombotic Thrombocytopenic Purpura:

32 (show all 20)
# Description HPO Frequency HPO Source Accession
1 proteinuria 32 occasional (7.5%) HP:0000093
2 hematuria 32 occasional (7.5%) HP:0000790
3 seizures 32 frequent (33%) HP:0001250
4 coma 32 frequent (33%) HP:0001259
5 confusion 32 frequent (33%) HP:0001289
6 stroke 32 frequent (33%) HP:0001297
7 myocardial infarction 32 occasional (7.5%) HP:0001658
8 thrombocytopenia 32 hallmark (90%) HP:0001873
9 acute kidney injury 32 very rare (1%) HP:0001919
10 reticulocytosis 32 hallmark (90%) HP:0001923
11 microangiopathic hemolytic anemia 32 hallmark (90%) HP:0001937
12 fever 32 occasional (7.5%) HP:0001945
13 diarrhea 32 frequent (33%) HP:0002014
14 abdominal pain 32 frequent (33%) HP:0002027
15 dyspnea 32 hallmark (90%) HP:0002094
16 headache 32 frequent (33%) HP:0002315
17 generalized muscle weakness 32 hallmark (90%) HP:0003324
18 arrhythmia 32 occasional (7.5%) HP:0011675
19 decreased serum creatinine 32 very rare (1%) HP:0012101
20 abnormal lactate dehydrogenase activity 32 frequent (33%) HP:0045040

UMLS symptoms related to Thrombotic Thrombocytopenic Purpura:


fever, tremor

MGI Mouse Phenotypes related to Thrombotic Thrombocytopenic Purpura:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.01 VWF SELE SELP THBD CD46 CFH
2 hematopoietic system MP:0005397 9.97 F3 VWF SELE ADAMTS13 SELP THBD
3 homeostasis/metabolism MP:0005376 9.97 VWF SELE ADAMTS13 SELP APOH THBD
4 immune system MP:0005387 9.86 F3 VWF SELE ADAMTS13 SELP THBD
5 mortality/aging MP:0010768 9.81 THBS1 F3 VWF SELE ADAMTS13 SELP
6 respiratory system MP:0005388 9.35 THBS1 F3 SELE SELP THBD
7 vision/eye MP:0005391 9.17 SELE ADAMTS13 SELP CD46 CFH THBS1

Drugs & Therapeutics for Thrombotic Thrombocytopenic Purpura

PubMedHealth treatment related to Thrombotic Thrombocytopenic Purpura: 63

Thrombotic thrombocytopenic purpura (TTP) can be fatal or cause lasting damage, such as brain damage or a stroke, if it's not treated right away.In most cases, TTP occurs suddenly and lasts for days or weeks, but it can go on for months. Relapses (flareups) can occur in up to 60 percent of people who have acquired TTP. Flareups also occur in most people who have inherited TTP.Plasma treatments are the most common way to treat TTP. Other treatments include medicines and surgery. Treatments are done in a hospital.

Drugs for Thrombotic Thrombocytopenic Purpura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
2
Clopidogrel Approved Phase 4,Phase 3 120202-66-6, 113665-84-2 60606
3
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
4 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
6 Fibrinolytic Agents Phase 4,Phase 3
7 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
8 Platelet Aggregation Inhibitors Phase 4,Phase 3
9 Prasugrel hydrochloride Phase 4 389574-19-0
10 Purinergic P2 Receptor Antagonists Phase 4,Phase 3
11 Purinergic P2Y Receptor Antagonists Phase 4,Phase 3
12
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
13
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
14
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
15
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177
16
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 5284616 6436030 46835353
17
Tacrolimus Approved, Investigational Phase 2, Phase 3,Not Applicable 104987-11-3 445643 439492
18
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
19
Dipyridamole Approved Phase 3 58-32-2 3108
20 Antifungal Agents Phase 3,Phase 2
21 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
22 Anti-Inflammatory Agents Phase 3,Phase 2
23 Antineoplastic Agents, Hormonal Phase 3,Phase 2
24 Calcineurin Inhibitors Phase 3,Phase 2,Not Applicable
25 Cyclosporins Phase 3
26 Dermatologic Agents Phase 3,Not Applicable
27 glucocorticoids Phase 3,Phase 2
28 Hormone Antagonists Phase 3,Phase 2
29 Hormones Phase 3,Phase 2
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
31 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable
32 Anti-Bacterial Agents Phase 2, Phase 3,Not Applicable
33 Antibiotics, Antitubercular Phase 2, Phase 3,Not Applicable
34 Peripheral Nervous System Agents Phase 3,Phase 2
35 Analgesics Phase 3
36 Anesthetics Phase 3
37 Anti-Arrhythmia Agents Phase 3
38 Anticonvulsants Phase 3
39 calcium channel blockers Phase 3
40 Calcium, Dietary Phase 3
41 Central Nervous System Depressants Phase 3
42 Tocolytic Agents Phase 3
43 Analgesics, Non-Narcotic Phase 3
44 Anti-Inflammatory Agents, Non-Steroidal Phase 3
45 Antipyretics Phase 3
46 Cyclooxygenase Inhibitors Phase 3
47
Acetaminophen Approved Phase 2 103-90-2 1983
48
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
49
Promethazine Approved, Investigational Phase 2 60-87-7 4927
50
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab Completed NCT00820469 Phase 4 Rituximab 375;rituximab 1000
2 VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel Completed NCT01684813 Phase 4 Prasugrel.;Clopidogrel
3 Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Withdrawn NCT01754545 Phase 4 Octaplas infusion and placebo (group 1);Octaplas infusion and placebo (group 2)
4 Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) Completed NCT00713193 Phase 3 Cyclosporine;Prednisone
5 Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura Completed NCT02553317 Phase 3
6 A Phase 3, Randomized, Controlled Study of Prophylactic and On-demand Treatment of cTTP With BAX 930 (rADAMTS13) Active, not recruiting NCT03393975 Phase 3
7 Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES) Active, not recruiting NCT02878603 Phase 3
8 Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care Not yet recruiting NCT03237819 Phase 3 Sulfate, Magnesium;Placebo - Concentrate
9 Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP) Terminated NCT00411801 Phase 3
10 Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) Terminated NCT00799773 Phase 3 Rituximab;Corticosteroids
11 Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke Terminated NCT01661322 Phase 3 Aspirin, Dipyradimole, Clopidogrel
12 Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus Terminated NCT00117702 Phase 2, Phase 3 Tacrolimus;Everolimus
13 The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) Unknown status NCT00937131 Phase 2 Rituximab
14 Rituximab in Patients With Relapsed or Refractory TTP-HUS Unknown status NCT00531089 Phase 2 Rituximab
15 Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP) Completed NCT01151423 Phase 2
16 Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Completed NCT00907751 Phase 2 rituximab
17 Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas Completed NCT00412542 Phase 2 Thalidomide;CPT-11
18 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Completed NCT01222715 Phase 2 Cyclophosphamide;Temsirolimus;Vinorelbine Tartrate
19 An Open-label Safety Study of S-888711 Completed NCT01129024 Phase 2 S-888711 0.5 mg tablet
20 Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) Recruiting NCT00953771 Phase 2 Danazol
21 Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura Recruiting NCT01554514 Phase 2
22 Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement Recruiting NCT02765854 Phase 2 Dexamethasone;Ixazomib;Lenalidomide
23 A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP) Not yet recruiting NCT03013114 Phase 2 Bortezomib
24 IdeS in Asymptomatic Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients Terminated NCT02854059 Phase 1, Phase 2
25 Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy Terminated NCT00726544 Phase 2 ARC 1779 Placebo;ARC1779 Injection;ARC1779 Injection;ARC1779 Injection
26 A Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered to Adult Subjects With Immune Thrombocytopenia (ITP) Terminated NCT01054443 Phase 2 placebo to S-888711;S-888711;S-888711;S-888711
27 Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura Withdrawn NCT00251277 Phase 1, Phase 2 Rituximab
28 Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP) Completed NCT02216084 Phase 1 Recombinant ADAMTS13
29 Influence of Extracorporeal Circulation During Cardiac Surgery on the Development of Postoperative Thrombotic Thrombocytopenic Purpura (TTP) Unknown status NCT01300117
30 Levels of Von Willebrand Factor Multimers and VWF-Cleaving Protease (ADAMTS-13) in Preterm and Neonate Unknown status NCT00701610
31 ADAMTS13 in Thrombotic Thrombocytopenic Purpura Completed NCT00426686
32 Early Predictive Factors of Cardiac and Cerebral Involvement in TMA Completed NCT02134171 Not Applicable
33 Promising Bimarker Prediction of Outcome of HELLP Syndrome. Completed NCT03246542
34 Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX Completed NCT00360685 Not Applicable Tac+MTX;TAC + MMF
35 Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome) Recruiting NCT01257269
36 Octaplas Adult TTP Trial Recruiting NCT01938404 Standard Plasma
37 Observational Study of the Use of octaplasLG®. Recruiting NCT03369314 octaplasLG®
38 A Prospective Study on the Long-Term Vascular Burden in TTP Patients Recruiting NCT03187652
39 The Role of Microparticles as a Biomarker Enrolling by invitation NCT02626663
40 Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP] Not yet recruiting NCT03519672
41 International Registry and Biorepository for TMA(Thrombotic Microangiopathy) Terminated NCT00593229

Search NIH Clinical Center for Thrombotic Thrombocytopenic Purpura

Cochrane evidence based reviews: purpura, thrombotic thrombocytopenic

Genetic Tests for Thrombotic Thrombocytopenic Purpura

Anatomical Context for Thrombotic Thrombocytopenic Purpura

MalaCards organs/tissues related to Thrombotic Thrombocytopenic Purpura:

41
Kidney, Brain, Heart, Skin, Endothelial, Liver, Testes

Publications for Thrombotic Thrombocytopenic Purpura

Articles related to Thrombotic Thrombocytopenic Purpura:

(show top 50) (show all 951)
# Title Authors Year
1
Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade. ( 29728803 )
2018
2
Insights into 3D Structure of ADAMTS13: A Stepping Stone towards Novel Therapeutic Treatment of Thrombotic Thrombocytopenic Purpura. ( 29304523 )
2018
3
Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report. ( 29357939 )
2018
4
The clinical features of cardiac involvement in patients with severe thrombotic thrombocytopenic purpura. ( 29752524 )
2018
5
Pediatric thrombotic thrombocytopenic purpura. ( 29889319 )
2018
6
Child-onset thrombotic thrombocytopenic purpura caused by p.R498C and p.G259PfsX133 mutations in ADAMTS13. ( 29763513 )
2018
7
Large vessel stroke as initial presentation of thrombotic thrombocytopenic purpura. ( 29437728 )
2018
8
ADAMTS13 Testing Methodologies and Thrombotic Thrombocytopenic Purpura (TTP): Conflicting Results Can Pose a Clinical Dilemma. ( 29970443 )
2018
9
Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature. ( 29855343 )
2018
10
An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura. ( 29222940 )
2018
11
Concurrent Presentation of Thrombotic Thrombocytopenic Purpura and Membranous Nephropathy. ( 29725652 )
2018
12
Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. ( 29356300 )
2018
13
Ticagrelor-induced thrombotic thrombocytopenic purpura: A case report and review of the literature. ( 29952973 )
2018
14
Myocardial Infarction as an Early Presentation in Thrombotic Thrombocytopenic Purpura: A Rare Case Series. ( 29761111 )
2018
15
Changes in plasma von Willebrand factor and von Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura: A case report. ( 29250148 )
2018
16
Intravenous immunoglobulin as salvage therapy for refractory thrombotic thrombocytopenic purpura. ( 29247542 )
2018
17
The Diagnostic Challenge of Acquired Thrombotic Thrombocytopenic Purpura in Children: Case Report and Review of the Literature. ( 29659973 )
2018
18
Neuro-Behcet's disease in a patient with thrombotic thrombocytopenic purpura. ( 29444324 )
2018
19
Does this patient with thrombotic thrombocytopenic purpura have a cardiac involvement? ( 29868970 )
2018
20
No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: The experience from the Ohio State University Registry. ( 29226481 )
2018
21
Schistocytosis occurs in severely anemic B12-deficient patients and does not imply thrombotic thrombocytopenic purpura. ( 29790646 )
2018
22
Relapsed/refractory thrombotic thrombocytopenic purpura treated with N-acetylcysteine: a case report. ( 29739267 )
2018
23
Nurses best practices for the management of thrombotic thrombocytopenic purpura. ( 29960714 )
2018
24
Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers. ( 29674502 )
2018
25
Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura. ( 29786866 )
2018
26
The utility of a fast turnaround ADAMTS13 activity in the diagnosis and exclusion of thrombotic thrombocytopenic purpura. ( 29687882 )
2018
27
Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single Institution Experience. ( 29966997 )
2018
28
The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective. ( 29945940 )
2018
29
Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20. ( 28815685 )
2017
30
Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera. ( 28596255 )
2017
31
Pseudo-thrombotic thrombocytopenic purpura presenting as multi-organ dysfunction syndrome: A rare complication of pernicious anemia. ( 28620491 )
2017
32
EB virus reactivation triggers thrombotic thrombocytopenic purpura in a healthy adult. ( 28702343 )
2017
33
A case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura. ( 27885868 )
2017
34
Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura. ( 29228282 )
2017
35
Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. ( 29296854 )
2017
36
Chikungunya Fever Presenting as Life Threatening Thrombotic Thrombocytopenic Purpura. ( 28792176 )
2017
37
Rare Presentation of Refractory Thrombotic Thrombocytopenic Purpura: Jejunal Stricture. ( 29340125 )
2017
38
Acquired Thrombotic Thrombocytopenic Purpura in a Patient with Pernicious Anemia. ( 28473932 )
2017
39
Acute disseminated melioidosis giving rise to pneumonia and renal abscesses complicated with thrombotic thrombocytopenic purpura in a post partum woman: a case report. ( 29187254 )
2017
40
Development of Thrombotic Thrombocytopenic Purpura in Association With the Monoclonal Antibody, Golimumab, Used to Treat Rheumatoid Arthritis, in a Case With Literature Review. ( 29293116 )
2017
41
ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy. ( 28940604 )
2017
42
Novel therapeutic approaches for thrombotic thrombocytopenic purpura. ( 28759473 )
2017
43
Therapeutic plasma exchange for thrombotic thrombocytopenic purpura with refractory thrombocytopenia. ( 29270999 )
2017
44
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. ( 29296701 )
2017
45
Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura. ( 29270517 )
2017
46
von Willebrand factor and its cleaving protease ADAMTS13 balance in coronary artery vessels: Lessons learned from thrombotic thrombocytopenic purpura. A narrative review. ( 28521259 )
2017
47
A novel homozygous frameshift mutation in Exon 7 of the ADAMTS13 gene in a patient with congenital thrombotic thrombocytopenic purpura from India: a case report. ( 28833243 )
2017
48
Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. ( 28671324 )
2017
49
Thrombotic Thrombocytopenic Purpura or Disseminated Intravascular Coagulation? ( 28904488 )
2017
50
Siblings with congenital thrombotic thrombocytopenic purpura. ( 28883277 )
2017

Variations for Thrombotic Thrombocytopenic Purpura

Expression for Thrombotic Thrombocytopenic Purpura

Search GEO for disease gene expression data for Thrombotic Thrombocytopenic Purpura.

Pathways for Thrombotic Thrombocytopenic Purpura

Pathways related to Thrombotic Thrombocytopenic Purpura according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.58 APOH F3 SELE SELP THBD THBS1
2
Show member pathways
11.92 ADAMTS13 ADAMTSL1 THBS1
3
Show member pathways
11.89 SELE SELP THBD
4
Show member pathways
11.81 F3 THBD VWF
5
Show member pathways
11.74 ADAMTS13 ADAMTSL1 THBS1
6 11.54 F3 SELE THBD
7 11.45 F3 THBS1 VWF
8
Show member pathways
11.31 ADAMTS13 ADAMTSL1 THBS1
9 11.16 CD46 CFH F3 THBD VWF
10 11.02 SELE SELP THBS1

GO Terms for Thrombotic Thrombocytopenic Purpura

Cellular components related to Thrombotic Thrombocytopenic Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 ADAMTS13 APOH CFH F3 SELE SELP
2 extracellular matrix GO:0031012 9.46 APOH F3 THBS1 VWF
3 platelet alpha granule GO:0031091 9.26 THBS1 VWF
4 cell surface GO:0009986 9.1 ADAMTS13 APOH CD46 F3 THBD THBS1

Biological processes related to Thrombotic Thrombocytopenic Purpura according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.86 SELE SELP THBS1 VWF
2 leukocyte migration GO:0050900 9.72 SELE SELP THBD
3 response to lipopolysaccharide GO:0032496 9.71 SELE SELP THBD
4 blood coagulation GO:0007596 9.62 ADAMTS13 F3 THBD VWF
5 negative regulation of endothelial cell proliferation GO:0001937 9.57 APOH THBS1
6 platelet degranulation GO:0002576 9.56 APOH SELP THBS1 VWF
7 response to tumor necrosis factor GO:0034612 9.52 ADAMTS13 SELE
8 leukocyte cell-cell adhesion GO:0007159 9.51 SELE SELP
9 negative regulation of endothelial cell migration GO:0010596 9.49 APOH THBS1
10 blood coagulation, intrinsic pathway GO:0007597 9.48 APOH VWF
11 leukocyte tethering or rolling GO:0050901 9.46 SELE SELP
12 negative regulation of blood coagulation GO:0030195 9.43 APOH THBD
13 positive regulation of blood coagulation GO:0030194 9.4 APOH THBS1
14 positive regulation of transforming growth factor beta production GO:0071636 9.37 CD46 THBS1
15 protein O-linked fucosylation GO:0036066 9.33 ADAMTS13 ADAMTSL1 THBS1
16 negative regulation of fibrinolysis GO:0051918 9.13 APOH THBD THBS1
17 hemostasis GO:0007599 8.92 ADAMTS13 F3 THBD VWF

Molecular functions related to Thrombotic Thrombocytopenic Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.62 ADAMTS13 SELP THBD THBS1
2 integrin binding GO:0005178 9.43 ADAMTS13 THBS1 VWF
3 oligosaccharide binding GO:0070492 9.16 SELE SELP
4 sialic acid binding GO:0033691 8.96 SELE SELP
5 heparin binding GO:0008201 8.92 APOH CFH SELP THBS1

Sources for Thrombotic Thrombocytopenic Purpura

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....